Medical Writing Vaccines and Immunotherapies Immuno-oncology: Harnessing our immune system to fight cancer
mew-27-1png

Volume 27, Issue 1 - Vaccines and Immunotherapies

Immuno-oncology: Harnessing our immune system to fight cancer

Abstract

The history of immunotherapy to treat cancer began in 1891 when the American surgeon William Coley performed intra-tumoural injections with inactivated bacteria in patients with advanced sarcoma, in an attempt to stimulate anti-tumour immunity. Modern immunotherapy gradually made its way over the last 50 years, as a better understanding of anti-cancer immunity has been gained. Immunotherapeutic agents target three essential steps in the immune response to tumour-associated antigens, namely antigen presentation, effector T-cell response, and inhibition of tumour-driven immunosuppression. Conventional chemotherapy and immunotherapy agents differ in their mode of action, predicted endpoints, and toxicities. The development and approval of immuno therapy drugs has therefore challenged our traditional view of conducting clinical trials. Many challenges with great promises still lie ahead, including combination therapies and individualised therapy based on patients’ predicted responses to treatments.

Download the full article

References

  1. Faries MB. Intralesional Immunotherapy for metastatic melanoma: the oldest and newest treatment in oncology. Crit Rev Oncog. 2016;21:65–73.
  2. Wiemann B, Starnes CO. Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994;64:529–64.
  3. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Am J Med Sci. 1893;105:487–511.
  4. Morrissey KM, Yuraszeck TM, Li C-C, et al. Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clin Transl Sci. 2016;9:89–104.
  5. Mataraza JM, Gotwals P. Recent advances in immuno-oncology and its application to urological cancers. BJU Int. 2016;118: 506–14.
  6. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121:1–14.
  7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
  8. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–89.
  9. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.
  10. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol. 2005;23:975–1028.
  11. Van den Eynde BJ, Boon T. Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res. 1997;27:81–6.
  12. Darrasse-Jèze G, Deroubaix S, Mouquet H, et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med. 2009;206:1853–62.
  13. Kober J, Leitner J, Klauser C, et al. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol. 2008;38:2678–88.
  14. Croft M, So T, Duan W, et al. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev. 2009;229:173–91.
  15. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4: 762–74.
  16. Marigo I, Dolcetti L, Serafini P, et al. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222:162–79.
  17. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mecha - nism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54:307–14.
  18. Bouzin C, Brouet A, De Vriese J, et al. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol. 2007;178:1505–11.
  19. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475:226–30.
  20. Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol. 2016;28:401–9.
  21. Ohta A. A Metabolic Immune checkpoint: adenosine in tumor microenvironment. Front Immunol. 2016;7:109.
  22. Kamta J, Chaar M, Ande A, et al. Advancing cancer therapy with present and emerging immuno-oncology approaches. Front Oncol. 2017;7:64.
  23. Galluzzi L, Vacchelli E, Bravo-San Pedro J-M, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014;5:12472–508.
  24. Kokate R. A systematic overview of cancer immunotherapy: an emerging therapy. Pharm Pharmacol Int J. 2017;5:1–6.
  25. Prowell TM, Theoret MR, Pazdur R. Seamless oncology-drug development. N Engl J Med. 2016;374:2001–3.
  26. Menis J, Litière S, Tryfonidis K, et al. The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. Ann Transl Med. 2016;4:267
  27. Emens LA, Butterfield LH, Hodi FS, et al. Cancer immunotherapy trials: leading a paradigm shift in drug development. J Immunother Cancer. 2016;4:42.
  28. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
  29. Kohrt HE, Tumeh PC, Benson D, et al. Immunodynamics: a cancer immuno - therapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer. 2016;4:15.
  30. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl. 1990 2009;45:228–47.
  31. Nishino M, Jagannathan JP, Ramaiya NH, et al. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010;195:281–9.
  32. Le Lay J, Jarraya H, Lebellec L, et al. irRECIST and iRECIST: the devil is in the details. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:1676–8.
  33. Tazdait M, Mezquita L, Lahmar J, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer Oxf Engl 2017;88:38–47.
  34. Ades F, Yamaguchi N. WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results? Ecancermedicalscience. 2015;9:604.
  35. Hodi FS, Hwu W-J, Kefford R, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:1510–7.
  36. Wang P-F, Chen Y, Song S-Y, et al. Immunerelated adverse events associated with anti- PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730.
  37. Haanen JB a. G, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:iv119-iv142.
  38. Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14: E10–21.
  39. Roselló S, Blasco I, García Fabregat L, et al. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:iv100- iv118.
  40. Regis SM. Patient navigation in immunooncology. Am J Manag Care. 2017;23:SP46–7.
  41. Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti- PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–7.

Search

Articles

Vaccines and immunotherapies
President's Column
A history of EMWA
EMWA News
An introduction to vaccines and immunotherapies
Immuno-oncology: Harnessing our immune system to fight cancer
Changing methods to assess targeted therapies in oncology
HIV vaccine clinical trials: An overview
Allergen immunotherapy in the European regulatory environment
Pharmacovigilance for vaccines and immunotherapies
Addressing vaccine hesitancy in writing
Results of the 2017 EMWA salary survey
Lay writing: Strategies for improving assent forms
The perils of the unknown: Missing data in clinical studies
Medical writing in China: Trends and opportunities
PhD student: A medical writer in the making!
News from the EMA
Medical Communications
Journal Watch
In the Bookstores
The Webscout
Lingua Franca and Beyond
Teaching Medical Writing
Good Writing Practice
Medical Devices
Getting Your Foot in the Door
Entering medical communications as a non-native English speaker
Out on Our Own

Member Login

Links

The Write Stuff Archive Contact Instructions for Authors Feature Article Template (Word) Journal Policies

Editoral Board

Editor-in-Chief:

Co-Editor:

Managing Editor

show all +

Associate Editors:

Section Editors:

Ad-hoc Editors:

  • Amy Whereat (SpeaktheSpeech Consulting, Asnieres sur Seine, France)

Editor Emeritus: